All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Why should we use CAR30 memory T cells to treat Hodgkin and T-cell lymphoma?
Bookmark this article
The Lymphoma Hub are pleased to present a series of expert interviews from the 2nd European CAR T Cell Meeting in Sitges, ES. In this video, Javier Briones from Hospital de la Santa Creu i Sant Pau, Barcelona, ES, explains why we should use CAR30 memory T cells to treat Hodgkin and T-cell lymphoma.
Javier Briones explains CAR T therapy for Non-Hodgkin lymphoma and B-cell malignancies have shown to be effective but this success has not translated to Hodgkin lymphoma. He discusses his new trial that will look into the generation of CAR products directed at CD30, that are rich in memory T cells with greater intratumor activity.
Why should we use CAR30 memory T cells to treat Hodgkin and T-cell lymphoma?
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
45 votes - 78 days left ...
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox